| References: |
SB-742457, also known as RVT-101, is a selective 5-HT6 receptor antagonist with potential cognition, memory, and learning-enhancing effects. It was under development by GlaxoSmithKline for the treatment of Alzheimer's disease and demonstrated some preliminary efficacy in phase II clinical trials. SB742457 can reverse age-related declines in delayed non-match-to-sample performance (DNMS). SB742457 shows increasing pro-cognitive effects in patients with AD. For the detailed information of SB-742457（RVT-101）, the solubility of SB-742457（RVT-101） in water, the solubility of SB-742457（RVT-101） in DMSO, the solubility of SB-742457（RVT-101） in PBS buffer, the animal experiment (test) of SB-742457（RVT-101）, the cell expriment (test) of SB-742457（RVT-101）, the in vivo, in vitro and clinical trial test of SB-742457（RVT-101）, the EC50, IC50,and affinity,of SB-742457（RVT-101）, For the detailed information of SB-742457（RVT-101）, the solubility of SB-742457（RVT-101） in water, the solubility of SB-742457（RVT-101） in DMSO, the solubility of SB-742457（RVT-101） in PBS buffer, the animal experiment (test) of SB-742457（RVT-101）, the cell expriment (test) of SB-742457（RVT-101）, the in vivo, in vitro and clinical trial test of SB-742457（RVT-101）, the EC50, IC50,and affinity,of SB-742457（RVT-101）, Please contact DC Chemicals. |
